These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22512568)

  • 1. Angiogenesis as a therapeutic target in breast cancer.
    Koutras AK; Starakis I; Lymperatou D; Kalofonos HP
    Mini Rev Med Chem; 2012 Oct; 12(12):1230-8. PubMed ID: 22512568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor and bevacitumab in breast cancer.
    Bando H
    Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antiangiogenetic agents in the treatment of breast cancer.
    Bareschino MA; Schettino C; Colantuoni G; Rossi E; Rossi A; Maione P; Ciardiello F; Gridelli C
    Curr Med Chem; 2011; 18(33):5022-32. PubMed ID: 22050750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and breast cancer: current therapeutic progress and future perspectives.
    Yang SX
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1715-25. PubMed ID: 19954282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumoral angiogenesis and breast cancer.
    Khosravi Shahi P; Soria Lovelle A; Pérez Manga G
    Clin Transl Oncol; 2009 Mar; 11(3):138-42. PubMed ID: 19293050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
    Lohmann AE; Chia S
    Curr Treat Options Oncol; 2012 Jun; 13(2):249-62. PubMed ID: 22350496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.
    Fakhrejahani E; Toi M
    Jpn J Clin Oncol; 2014 Mar; 44(3):197-207. PubMed ID: 24474817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-angiogenic therapy in breast cancer].
    Tanaka R; Tamura K
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):153-6. PubMed ID: 24743193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
    Pavlidis ET; Pavlidis TE
    World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Zhang M; Liu J; Liu G; Xing Z; Jia Z; Li J; Wang W; Wang J; Qin L; Wang X; Wang X
    Cancer Lett; 2021 Nov; 520():422-433. PubMed ID: 34389434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.